Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Torrance, California Clinical Trials

A listing of Torrance, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (9) clinical trials

An Investigational Immuno-therapy Study of Nivolumab Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either: Group 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and dexamethasone OR Group 3: nivolumab, ...

Phase

2.47 miles

Learn More »

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants taking "dummy" medicine. In addition to taking the medicine, participants will ...

Phase

3.2 miles

Learn More »

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

A randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of QAW039, compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult and adolescent ( 12 years) patients with uncontrolled asthma with respect to change from baseline in forced expiratory volume in 1 second ...

Phase

4.17 miles

Learn More »

A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Patients will be enrolled in two groups. Group 1 will enroll patients who are not candidates for surgery. Group 2 will enroll patients who are surgical candidates. Patients from both groups will be evaluated for tumor response and progression by MRI every 8 weeks until disease progression or discontinuation from ...

Phase

4.17 miles

Learn More »

Transcranial Direct Current Stimulation in Major Depression

Transcranial direct current stimulation (tDCS), a noninvasive neuromodulation technique, applied to the left dorsolateral prefrontal cortex (DLPFC) can reduce depressive symptoms and improve cognitive control in major depressive disorder (MDD). Such findings suggest modulation of top down prefrontal-limbic circuits, which are functionally distinct from ventro-limbic networks and include reciprocally connected ...

Phase N/A

4.17 miles

Learn More »

QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors

This is a phase 2, two-cohort, single-arm open-label study that will assess the efficacy of AMG 337 based on ORR in subjects with advanced or metastatic solid tumors that overexpress MET or harbor METex14del mutations resulting in MET exon 14 skipping. MET overexpression will be determined by quantitative proteomics with ...

Phase

7.35 miles

Learn More »

QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma

The phase 2 study will assess efficacy of AMG 337 in subjects with advanced or metastatic clear cell sarcoma that contains the EWSR1-ATF1 gene fusion. The study will be conducted using Simon's two-stage optimal design. The null hypothesis of Simon's two-stage design states that the ORR will be 40% (poor ...

Phase

7.35 miles

Learn More »

A Study of Oral Contraception Under Simulated OTC Conditions

Subjects will be primarily recruited via passive recruiting methods, such as in-store posters, direct mail postcards, and digital space advertising. Respondents to advertisements will either call Clinical Research Organization (CRO) call center or visit the study website for initial screening (during which data regarding age, gender, and minimal study exclusion ...

Phase

9.05 miles

Learn More »

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

This is study is a placebo controlled study where subjects with moderate to severe atopic dermatitis will be randomized (1:1:1:1) to receive ASN002 at 40 mg, 60 mg, or 80 mg, or placebo once daily for 12 weeks. Eligible subjects will get the opportunity to enroll in the 24 month ...

Phase

9.31 miles

Learn More »